On 21 May 2024, Celltrion announced positive two-year results from its extended LIBERTY studies (LIBERTY-CD and LIBERTY-UC) for Zymfentra™ (infliximab-dyyb) in adults with moderately to severely active Crohn’s disease and ulcerative colitis after induction with intravenous infliximab. Celltrion reports that the findings support the long-term efficacy and safety of Zymfentra™.
Zymfentra™ was the first subcutaneous formulation of infliximab approved by the FDA in October 2023. Celltrion launched Zymfentra in the US in March 2024. A formulation patent for Zymfentra was granted in the US on 9 April 2024.